There seems to be this wide misconception amongst retail investors that new pharmaceutical treatments = massive production costs, probably thanks to the cell and gene therapies that have emerged the last decade. As I'm sure you are aware; the cost to produce RC220 pales in comparison.
This is important for two reasons:
Our current trial design (in combination with a generic) is incredibly cheap relative to other drug development biotech's basket trials in combination with non-generics.
The Triangle report includes an indicative market price of RC220 at ~US$60k/patient. That's great when your gross margin is ~US$59k - not so much if it were ~US$1k.
There's been a few novice retail investors appear on this board and assert that "you can't run a trial for the cash RAC has on hand"... So I am not sure why ensuring existing and potential investors are aware of the above is "dumb"?
Note that there seems to be a bit of excitement re the possibility for Zan + PD1 in the near future (especially after the recent interview with Simon). That would be incredibly expensive and we'd need a partner or massive raise to cover the cost of the PD1. Noting that Astex have agreed to free-issue decitabine if we can ever manage to get that trial off the ground...
RAC Price at posting:
$1.20 Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)